Pfizer Inc.'s new antibacterial drug Sivuono has been approved in China.

Pfizer Inc. (PFE.US) announced today (June 30) that its new antibiotic drug Zavicefta (sodium avibactam and ceftazidime for injection, hereinafter referred to as "ceftazidime/avibactam") has received official approval from the National Medical Products Administration for the treatment of complicated intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) caused by Gram-negative bacteria where limited or no alternative treatment is available for adults. Zavicefta is the first fixed-dose combination of a -lactam antibiotic/-lactamase inhibitor to cover all carbapenemase-producing enterobacteriaceae (CRE) enzymes. Through its unique formulation, Zavicefta not only covers KPC and OXA-48 carbapenemases but also effectively targets bacteria producing MBL, overcoming the issue faced by previous -lactamase inhibitor fixed-dose combinations in covering MBL-producing bacteria. It has broad-spectrum inhibitory activity, improving patient treatment outcomes while reducing the risk of resistance emergence. This approval will help further combat the trend of bacterial resistance, enhance the precise coverage of new antibiotics for CRE infections, and advance precision treatment in the field of anti-infectives, which is of significant importance for public health and innovative treatment paradigms. Jean-Christophe Pointeau, President of Pfizer Inc. China and Chairman of RDPAC, said, "Antibiotic resistance is a common global challenge, and Pfizer Inc. has been deeply involved in the field of anti-infectives for many years, always dedicated to the innovation of anti-infective drugs to assist in clinical management of resistant bacterial infections and protect lives and health. The approval of Zavicefta will once again expand the treatment boundaries of carbapenem-resistant Gram-negative bacteria (CRO), providing innovative treatment solutions for clinical targets, benefiting more infected patients clinically, and further combating the development of resistance trends. We thank the National Medical Products Administration and other relevant departments for their support of new antibiotics. Pfizer Inc. will continue to strive to address the health challenges brought by antibiotic resistance and continuously implement the mission of 'bringing breakthrough innovation that changes patients' lives'."